# Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

Source: https://onco.cc/trials/nct06797635/  
OnCo record `nct06797635` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Patritumab deruxtecan, Pembrolizumab, Carboplatin, Doxorubicin, Epirubicin and Cyclophosphamide in HR-positive / HER2-negative breast cancer, run by Merck Sharp & Dohme LLC, now recruiting.

## Summary

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) is a phase 2 interventional study registered as NCT06797635 by Merck Sharp & Dohme LLC, with 372 participants planned, started 2025-03-20 and due to reach its primary completion in 2029-12-31. Interventions recorded: Patritumab deruxtecan, Pembrolizumab, Paclitaxel, Carboplatin, Doxorubicin hydrochloride and Epirubicin hydrochloride.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06797635
- Phase: 2
- Setting: An Open-label Randomized Phase 2 Study to Evaluate Safety and Efficacy of Patritumab Deruxtecan Plus Pembrolizumab Administered Either Before or After Carboplatin/Paclitaxel Plus Pembrolizumab Compared With Pembrolizumab in Combination With Chemotherapy Followed by Surgery and Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer (HERTHENA-Breast03)
- Sponsor: Merck Sharp & Dohme LLC
- Enrolled: 372

## Sources

- ClinicalTrials.gov NCT06797635: https://clinicaltrials.gov/study/NCT06797635

## Connected records

- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Doxorubicin](https://onco.cc/drugs/doxorubicin/), [Epirubicin](https://onco.cc/drugs/epirubicin/), [Patritumab deruxtecan](https://onco.cc/drugs/patritumab-deruxtecan/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [Daiichi Sankyo](https://onco.cc/companies/daiichi-sankyo/), [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct06797635.json